Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital G. Mazzini, ASL 4 Teramo, Italy.
Int J Immunopathol Pharmacol. 2013 Apr-Jun;26(2):299-304. doi: 10.1177/039463201302600203.
Anxiety disorders (Ads) are the most common type of psychiatric disorders, Pharmacologic options studied for treating ADs may include benzodiazepines, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRIs), noradrenergic and specific serotonergic antidepressants (NaSSA) and serotonin and noradrenaline reuptake inhibitors (SNRIs). Agomelatine, a new melatonergic antidepressant, has been shown effective in various types of mood disorders. Moreover, some evidence points towards a possible efficacy of such a drug in the treatment of ADs. Therefore, the aim of this review was to elucidate current (facts and views) data on the role of agomelatine in the treatment of ADs. The trials evaluating agomelatine in the treatment of generalized anxiety disorder are few but, overall, encouraging in regards to its efficacy. However, further randomized, placebo-controlled studies on larger samples use are needed. Apart from some interesting case reports, no large studies are, to date, present in literature regarding agomelatine in the treatment of other ADs, such as panic disorder, social anxiety disorder, obsessive-compulsive disorder and post-traumatic stress disorder. Therefore, the clinical efficacy and the relative good tolerability of agomelatine in generalized anxiety (GAD) warrants further investigation in ADs.
焦虑障碍（Ads）是最常见的精神障碍类型，研究用于治疗 Ads 的药物选择可能包括苯二氮䓬类、三环抗抑郁药（TCA）、选择性 5-羟色胺再摄取抑制剂（SSRIs）、去甲肾上腺素和特异性 5-羟色胺能抗抑郁药（NaSSA）和 5-羟色胺和去甲肾上腺素再摄取抑制剂（SNRIs）。阿戈美拉汀是一种新的褪黑素能抗抑郁药，已被证明对各种类型的情绪障碍有效。此外，一些证据表明，这种药物可能对治疗 Ads 有效。因此，本综述的目的是阐明阿戈美拉汀在治疗 Ads 中的作用的当前（事实和观点）数据。评估阿戈美拉汀治疗广泛性焦虑症的试验很少，但总体上，其疗效令人鼓舞。然而，需要进一步的、更大样本量的、随机、安慰剂对照研究。除了一些有趣的病例报告外，迄今为止，关于阿戈美拉汀治疗其他 Ads（如惊恐障碍、社交焦虑障碍、强迫症和创伤后应激障碍）的大型研究在文献中均未见报道。因此，阿戈美拉汀在广泛性焦虑（GAD）中的临床疗效和相对良好的耐受性值得进一步研究。
